• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viral Immunol . Production and Evaluation of Anti-Sera Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants Using a Syrian Hamster Mode

tetano

Editor, Senior Moderator
Viral Immunol


. 2026 Mar 4:8828245261424872.
doi: 10.1177/08828245261424872. Online ahead of print.
Production and Evaluation of Anti-Sera Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants Using a Syrian Hamster Model

Yong Jun Choi[SUP] 1 [/SUP], Bo Min An[SUP] 1 [/SUP], Sang Won O[SUP] 1 [/SUP], Jeong-Hyun Nam[SUP] 1 [/SUP], Eun Ju Lee[SUP] 1 [/SUP], Il-Hwan Kim[SUP] 1 [/SUP], Jee Eun Rhee[SUP] 1 [/SUP], Eun-Jin Kim[SUP] 1 [/SUP]


Affiliations
Abstract

The continuous emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continues to influence the global coronavirus 2019 (COVID-19) pandemic. Even vaccinated individuals or those with prior infections may experience reinfection, depending on the immune evasion capacity of the circulating variants. Therefore, analyses of variant characteristics and immune escape are critical for informing public health policy. However, as COVID-19 has been downgraded in terms of infectious disease classification, the availability of patient sera has become increasingly limited, restricting the timely immunological analyses of emerging variants. To address this challenge, we established an antiserum production and neutralization assay system using a hamster model and demonstrated the utility of this animal serum-based approach. In this study, antisera against 10 circulating SARS-CoV-2 variants were generated in golden Syrian hamsters, and they showed high titer of humoral and neutralizing antibody using enzyme-linked immunosorbent assay and plaque reduction neutralization test (PRNT) assay. In addition, we compared serum from an unvaccinated patient (n = 1) infected with the BA.5 variant with serum from a BA.5-infected hamster (n = 1). Although the number of comparable samples was limited, the PRNT[SUB]50[/SUB] titer patterns in serum from an unvaccinated individual infected with BA.5 and in hamster antisera were similar. These findings indicate that antisera generated in the hamster model can provide timely immunogenicity assessments of newly emerging SARS-CoV-2 variants, thereby contributing to the rapid characterization of variant immune escape and the generation of essential data for future public health preparedness.

Keywords: COVID-19; alternative antibodies; golden Syrian hamster; humoral immunity; neutralizing antibody.

 
Back
Top